The data in the ASH abstract published today is from a June 2, 2023 data cut and will include new data with a median follow-up of 26.5 months.

As detailed in the abstract, 38 patients were evaluable for efficacy and safety analysis, based on a median follow-up of 22 months following treatment.

Related: Analysts Stay Bullish On Arcellx's CART-ddBCMA's Long-term Therapeutic Potential.

These evaluable patients comprised the dose escalation cohorts for the first dose level (100 (+/- 20) million CAR+ T cells, n=6) and the second dose level (300 (+/- 20) million CAR+ T cells, n=6), and a dose expansion cohort at 100 (+/- 20) million CAR+ T cells (n=26).

Of the 38 evaluable patients with a median follow-up of 22 months, a 100% overall response rate (ORR) was achieved in all patients.

29 of 38 evaluable patients achieved a complete response (CR) or a stringent complete response (sCR) (> CR rate, 76%)

35 patients achieved a very good partial response or higher (>VGPR rate, 92%)

The median duration of response, progression-free survival (PFS), and overall survival were not reached at the time of the June 2, 2023 data cut because 25 of 38 (66%) evaluable patients had ongoing responses.

The Kaplan-Meier method estimated PFS rates for 6, 12, and 18 months were 92%, 74%, and 67% respectively.

Durable responses were also observed in patients with high-risk features and high-risk cytogenetics.

Price Action: ACLX shares are up 17.30% at $40.35 on the last check Thursday.